Rationale: The Notch signaling pathway is important for cell-cell communication that controls tissue formation and homeostasis during embryonic and adult life, but the precise cell targets of Notch signaling in the mammalian heart remain poorly defined. Objective: To investigate the functional role of Notch signaling in the cardiomyocyte compartment of the embryonic and adult heart. Methods and Results: Here, we report that either conditional overexpression of Notch1 intracellular domain (NICD1) or selective silencing of Notch signaling in the embryonic cardiomyocyte compartment results in developmental defects and perinatal lethality. In contrast, augmentation of endogenous Notch reactivation after myocardial infarction in the adult, either by inducing cardiomyocyte-specific Notch1 transgene expression or by intramyocardial delivery of a Notch1 pseudoligand, increases survival rate, improves cardiac functional performance, and minimizes fibrosis, promoting antiapoptotic and angiogenic mechanisms. Conclusions: These results reveal a strict requirement for cell-autonomous modulation of Notch signaling during heart morphogenesis, and illustrate how the same signaling pathway that promotes congenital heart defects when perturbed in the embryo can be therapeutically redeployed for the treatment of adult myocardial damage. (Circ Res. 2010;106:559-572.)
C ongenital or acquired heart disease (HD) remains the leading cause of mortality in the young and the old. 1 Congenital HD is the most frequent form of human birth defects, occurring in 1% of the population worldwide with bicuspid aortic valve and septation defects being the most common manifestations. 1 The acquired form of HD occurs in later life, with longstanding hypertension, myocardial infarction (MI), and subtle congenital defects being the main causes. 2 A precise understanding of the molecular mechanisms that govern cardiac development is a promising route for deciphering the causes of congenital malformation and designing new therapeutics for acquired HD.
Notch pathway mutations in humans and mice have implicated this evolutionarily conserved signaling cascade in congenital and acquired forms of HD. 3 Genetic evidence from Drosophila indicates that Notch signals influence proliferation, differentiation and apoptotic events, suggesting that the precise outcome of Notch activation is dependent on gene dosage and cellular context. 4 Four Notch receptors (Notch1-4) and 5 ligands (Delta-like1, -3, -4, and Jag1-2) have been described in mammals. Ligand-receptor interactions trigger the ␥-secretase-mediated proteolytic cleavage of the Notch intracellular domain (NICD), which translocates to the nucleus and forms a transcription-activating complex with Recombination signal binding protein for immunoglobulin J (Rbp-J). Conformational changes in the NICD-Rbp-J complex release transcriptional repressors and recruit activators such as Mastermind-like (MAML) proteins to Notch target gene promoters. 5 Hairy and enhancer of split (Hes) and Hes-related (Hey) families of transcriptional repressors comprise well-documented Notch target genes. 6 In humans, the autosomal dominant disorder Alagille syndrome (AGS) has been linked to Jag1 and Notch2 mutations. 7, 8 One of the syndrome's clinical manifestations is congenital HD, including pulmonary artery stenosis, enlarged right ventricle, and atrial (ASD) and ventricular (VSD) septation defects. 3 Consistent with a central role for Notch signaling in heart development, mouse null mutants for Jag1, Notch1, Notch2, and Rbp-J display early embryonic lethality caused by multiple cardiac defects. 9 -12 The actions of Notch in heart morphogenesis are spatially and temporally diverse; although Notch signaling is required for ventricular myocardial differentiation, 9, 13 cardiomyocyte-specific ablation of Notch1 does not affect cardiac development in mice, 14 suggesting that Notch pathway regulates cardiogenesis by signaling in nonmuscle cell types of the embryonic heart, such as the adjacent endocardium, 9 as well as earlier in mesodermal development. 15 Several lines of evidence also implicate Notch signaling as a potent modulator of regeneration in the adult. Studies on Xenopus tail, 16 medaka fin, 17 and mammalian liver 18 regeneration have linked Notch signaling with tissue regeneration. In the mouse, reactivation of Notch signals in models of brain ischemia 19 and skeletal muscle injury 20 promotes tissue repair. In the heart, activation of the Notch pathway precedes cardiac regeneration in zebrafish, a model organism with remarkable reparative capacity. 21 Endogenous Notch signaling is downregulated in the adult mammalian heart, 22, 23 which may underlie its poor regenerative prognosis. Indeed, genetic ablation of Notch1 gene specifically in mouse cardiomyocytes results in cardiac hypertrophy, fibrosis and compromised function under stress conditions, 14 whereas injection of a viral vector expressing the Notch1 intracellular domain (NICD1) into infarcted mouse hearts improves hemodynamic function. 23 In vitro, Notch activation induces cell cycle reentry in quiescent cardiomyocytes 22, 24 and plays an important role in cardiac cell differentiation. 25, 26 Taken together, these studies highlight the complexity of functions played by Notch1 signaling during heart morphogenesis and adult cardiac repair.
To characterize the role of Notch signaling specifically in the differentiated cardiomyocyte compartment of developing and adult hearts, we used conditional and inducible mouse mutagenic models. Selective inhibition of Notch signaling or overexpression of NICD1 (which signals cell autonomously) in cardiomyocytes of the embryonic heart led to morphological defects and embryonic and perinatal lethality. In contrast, supplementing the transient de novo activation of the Notch signaling pathway after cardiac infarction with sustained induction of a cardiomyocyte-restricted NICD1 transgene blunted myocardial injury by promoting cardiomyocyte survival. The therapeutic relevance of this observation is supported by direct intramyocardial delivery of a Notch1 pseudoligand, which enhanced neovascularization and antiapoptotic signals in the injured heart. We conclude that aberrant Notch signaling in differentiated cardiomyocytes perturbs normal morphogenesis of the developing heart, whereas in a regenerative context, cardiomyocyte-specific Notch signaling can be beneficially redeployed for the treatment of acquired HD.
Methods
All mouse procedures were approved by European Molecular Biology Laboratory Monterotondo Ethical Committee (Monterotondo, Italy) and were in accordance with national and European regulations. Experimental protocols are described in the expanded Methods section available in the Online Data Supplement at http://circres. ahajournals.org.
Results

Notch1 Signaling Is Activated in Embryonic and Adult Cardiomyocytes
Notch receptors exhibit a dynamic expression pattern during cardiac development. 10, 27, 28 In particular, Notch1 is highly induced in the endocardium during early (embryonic day [E]8.5 to E10.5) cardiogenesis. 9, 29 In addition, we detected the activated form of Notch1 receptor (NICD1) in the nucleus of atrial and ventricular cardiomyocytes at later stages in the embryonic (E13.5) and neonatal (postnatal day [P]1) heart, performing double immunofluorescence staining for NICD1 and the cardiomyocyte marker ␣-actinin ( Figure  1A and 1B).
In the adult, Notch1 activity has been documented in cardiomyocytes 22, 23 and cardiac precursor cells. 14, 30 Correspondingly, NICD1 activity was detected in the nuclei of cardiomyocytes ( Figure 1C ), as well as in endothelial and smooth muscle cells of the cardiac vessels (Online Figure I) , which is in agreement with recent observations during avian coronary development. 31 Thus, active Notch1 signaling persists in embryonic and postnatal hearts, leading us to study the mechanisms whereby Notch1 receptor signaling in the cardiomyocyte compartment mediates heart morphogenesis and repair.
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Selective Overexpression of NICD1 in Cardiomyocytes Results in Multiple Cardiac Defects
To gain insight into the role of Notch1 receptor in embryonic cardiomyocytes, we bred transgenic mice carrying a single copy of an NICD1 floxed allele (CAG-CAT-NICD1) 15 with ␣MyHC-Cre transgenic mice 32 to achieve cardiomyocytespecific NICD1 overexpression. ␣MyHC-Cre recombinase expression initiates at E8.5, peaks at birth and is maintained at high levels during postnatal life in both atrial and ventricular cardiomyocytes. 32 Double transgenic offspring, hereafter referred to as NICD1-COE (cardiomyocyte overexpression), were born close to Mendelian frequency (20.1% instead of 25%) but displayed perinatal lethality caused by multiple cardiac defects. Hence, only a subgroup of NICD1-COE reached weaning (5.1% instead of 25%) and died around 3 to 4 months of age (Online Table I ). To confirm Notch gain-offunction, we assessed the cardiac expression of the Notch targets Hey1, Hey2, and Hes1 at P1. Relative to control, NICD1-COE samples showed upregulation of the Hey1, Hey2 and Hes1 mRNA levels (Figure 2A ), indicating constitutive activation of Notch signaling. As expected, NICD1 and HES1 protein levels were significantly increased in the NICD1-COE heart compared to control ( Figure 2B ). Additionally, double staining for ␣-actinin and NICD1 proved an increase in the number of NICD1 positive cardiomyocytes in the neonatal NICD1-COE heart, suggesting a cell-autonomous mode of action for NICD1 (Online Figure II, A) .
To decipher the cause of perinatal lethality in NICD1-COE mice as well as the premature death of the few perinatal survivors, which reached 3 to 4 months of age, cardiac morphology was examined at various developmental stages. Whole mount analysis ( Figure 2C and 2D, first image) revealed an increase in NICD1-COE heart size when compared to control sibs, with a readily enlarged right atrium and increased heart-to-body weight ratio at all stages examined (Online Figure II, B ). Trichrome staining on longitudinal sections revealed thick myocardial walls in the neonatal and adult NICD1-COE heart ( Figure 2C and 2D, second image), suggesting cardiomyocyte hyperplasia. Notably, NICD1-COE mice displayed a complete penetrance of ASDs at various postnatal stages ( Figure 2C and 2D, third image; and data not shown), whereas combined ASD and VSD were present in 80% of the NICD1-COE mice examined at P1 ( Figure 2C , fourth image), indicating that left-to-right shunting of oxygenated and deoxygenated blood may have caused circulatory distress and perinatal lethality. NICD1-COE mice that reached adulthood also displayed ASD ( Figure 2D , third and fourth images) and impaired cardiac function (Online Figure 
NICD1-COE Animals Exhibit Cardiac Hyperplasia and Impaired Differentiation
To assess whether excessive cardiomyocyte proliferation (cardiac hyperplasia) could be responsible for the thick myocardial walls observed in NICD1-COE mice, immunohistochemical (DAB) and double fluorescence staining for the mitotic (G 2 /M phase) marker phospho-Hist3 and ␣-actinin was performed on tissue sections from neonatal hearts. Increased phospho-Hist3 activity in cardiomyocytes was observed in all cardiac chambers of the NICD1-COE mice when compared to control ( Figure 3A and 3B), with differences reaching statistical significance at the right side of the heart ( Figure 3B ), suggesting that the thick NICD1-COE myocardial walls are the result of excessive cardiomyocyte proliferation. To determine whether cardiac differentiationspecific gene expression was affected in NICD1-COE animals, we analyzed the transcript levels of early cardiac differentiation markers. Apart from GATA binding protein 4 (Gata4) and myosin heavy chain 6 (Myh6), NICD1-COE hearts displayed increased expression levels of myosin heavy chain 7 (Myh7), atrial natriuretic peptide (Anp), brain natriuretic peptide (Bnp), and NK2 transcription factor related, locus 5 (Nkx2.5) at the neonatal stage (P1), suggesting impairment in myocardial differentiation ( Figure 3C ). Glucose transporter 1 (Glut1) mRNA was also upregulated in NICD1-COE hearts, indicating anabolic conditions ( Figure  3C ). Our data confirm that constitutive Notch1 signaling in the cardiomyocyte compartment sustains proliferation and perturbs differentiation, consistent with its role in promoting cell growth. 4
Silencing of Notch Signaling Perturbs Cardiac Morphogenesis
To unravel the role of Notch signaling specifically in cardiomyocytes and bypass possible Notch1-Notch2 redundancy issues, 33 we exploited the conditional dominant negative Maml1 (Maml1 DN ) line previously described as a genetic tool for pan-Notch pathway inhibition in vivo, 34, 35 which inhibits canonical Notch signaling by all four mammalian Notch receptors. 35, 36 When homozygous Maml1 DN/DN mice were bred with ␣MyHC-CRE transgenics, both ␣MyHC-CRE/ ϩ;Maml1 DN/ϩ and ␣MyHC-CRE/ϩ;Maml1 DN/DN offspring were born at Mendelian ratios, were viable and fertile (Online Table I ). Histological analysis of neonatal ␣MyHC-CRE/ϩ; Maml1 DN/DN hearts revealed occasionally thinner right ventricular (RV) walls, whereas other cardiac structures appeared normal ( Figure 4A ). Assessment of cardiac performance by echocardiography on adult ␣MyHC-CRE/ϩ;Maml1 DN/DN animals revealed no functional abnormalities ( Figure 4B ). These findings suggest a regional requirement for myocardial Notch signaling in RV morphogenesis; a notion further supported by a recent study where increased NICD1 activity was observed at the RV of the developing heart. 29 To assess the role of Notch signaling earlier in cardiogenesis, homozygous Maml1 DN/DN mice were bred with the Nkx2.5-CRE knock-in line, which allows robust expression of Maml1 DN from E7.0 throughout development in all cardiac muscle cells. 37 Interestingly, a small fraction of heterozygous Nkx2.5-CRE/ϩ;Maml1 DN/ϩ offspring displayed embryonic lethality at E12.5 caused by abnormal atrial and ventricular development ( Figure 4C ). However, the majority of Nkx2.5-CRE/ϩ;Maml1 DN/ϩ mutants were born and displayed perinatal lethality (Online Table I ) caused by ASD, VSD and abnormal (hypoplastic) RV formation ( Figure 4D ). Importantly, no alive Nkx2.5-CRE/ϩ;Maml1 DN/ϩ mutants were found at weaning (P21) (Online Table I ). The variability in phenotypic defects observed in the Nkx2.5CRE/ϩ; Maml1 DN/ϩ may be attributed to the functional competition between endogenous Maml1 protein and the Maml1 DN mutant; however, these data suggest a requirement for cardiomyocyte-derived Notch signaling in early cardiac morphogenesis.
Transient De Novo Notch Signaling Activation Following MI
The activation of Notch signaling in response to cardiac injury was assessed in a mouse model of MI. 38 NICD1 nuclear activity was detected in cardiomyocytes at the border zone (BZ) of the injury, as well as at the epicardial cell layer close to the BZ 1 week after MI (Online Figure  III, A) . Analysis by quantitative (q)RT-PCR of transcripts encoding Jag1, Notch1, Notch2, Notch3, and Notch4, and the Notch targets Hes1, Hey2 and Hey1 at several time points following MI revealed increased expression within the first week for all genes with the exception of Hey1 (Online Figure III 
Inducible Redeployment of Notch1 Signaling in Cardiomyocytes Blunts Myocardial Injury by Promoting Cell Survival
Because reactivation of Notch signaling leads to improved regeneration in mouse models of brain ischemia 19 and skeletal muscle injury, 20 we tested the potentially beneficial effects of sustained Notch signaling in the cardiomyocyte compartment of the infarcted heart. Tamoxifen-inducible ␣MyHC-mER-CRE-mER transgenics 39 were bred with the CAG-CAT-NICD1 mice thereby allowing induction of cardiomyocyte-specific NICD1 overexpression. Double transgenic offspring were generated (referred to as mER-CRE-mER; NICD1 hereafter) and their response to MI was evaluated. In tests of recombination efficiency, ␣MyHC-mER-CRE-mER line crossed with the ROSA26;LacZ-loxP reporter 40 progressively increased the number of recombined cardiomyocytes (X-gal-positive cells) after 1, 2, and 3 weeks of tamoxifen Figure V) . Similarly, NICD1 protein levels were gradually upregulated in the heart of mER-CRE-mER;NICD1 mice after 1, 2, and 3-week tamoxifen administration, confirming inducible Notch signaling activation in adult cardiomyocytes (Online Figure V) . To maximize recombination and minimize the risks of adverse effects caused by prolonged NICD1 levels, we subjected control and mER-CRE-mER;NICD1 mice to MI 1 week after the tamoxifen diet initiation. Tamoxifen diet was maintained for an extra week following MI (when myocardial injury is complete 41 ); subsequently mice were transferred to normal diet and euthanized 4 weeks after MI ( Figure 5A ). This experimental scheme was followed because intraperitoneal administration of tamoxifen or force-feeding with tamoxifen did not lead to reproducible results in tests of gene recombination efficiency.
diet (Online
Under basal conditions (sham operation), overexpression of NICD1 in cardiomyocytes did not affect cardiac size ( Figure 5A ), animal survival ( Figure 5C ), and cardiac performance ( Figure 5D through 5F). However, mER-CRE-mER;NICD1 mice displayed improved survival rate and cardiac function compared to controls at 1, 2, and 4 weeks following MI ( Figure 5C through 5F) . Moreover, the heart weight/body weight ratio was significantly downregulated in mER-CRE-mER;NICD1 mice 4 weeks after MI, indicating that adverse myocardial remodeling and dilation are curtailed in the mutants ( Figure 5A ). Indeed, trichrome staining confirmed reductions in replacement fibrosis and cardiac dilation in the mER-CRE-mER;NICD1 mice 4 weeks after MI ( Figure 5B ).
In view of the increased cardiomyocyte proliferation observed in the neonatal NICD1-COE heart, staining for the cell cycle marker Ki67 and the mitotic marker phospho-Hist3 was performed on infarcted mER-CRE-mER;NICD1 hearts. The numbers of Ki67 positive cardiomyocytes were significantly increased in the mER-CRE-mER;NICD1 heart at 2 and 28 days after infarction ( Figure 6A ), suggesting that Notch signaling activation induces cell cycle reentry in adult cardiomyocytes. However, no significant differences were observed in the number of phospho-Hist3 positive cardiomyocytes at 2 and 28 days following MI ( Figure 6B ), indicating that Notch signaling activation triggers incomplete cell cycle progression in adult cardiomyocytes. Importantly, blockade of apoptosis was implicated in Notch-1 mediated cardioprotection, as the numbers of apoptotic cells were significantly decreased in the left ventricular (LV) wall of mER-CRE-mER;NICD1 mice at 2 ( Figure 6C ) and 28 (Online Figure VI ) days after MI, indicating that Notch1 signaling promotes cell survival in the injured heart. Additionally, TUNEL assay accompanied by costaining for ␣-actinin demonstrated reduced numbers of TUNEL positive cardiomyocytes in the heart of mER-CRE-mER;NICD1 animals (7.72% versus 3.25%, PϽ0.01) at 2 days after infarction ( Figure 6D ), revealing cell autonomous antiapoptotic effects of Notch activation in the cardiomyocyte compartment.
To confirm the effects of Notch signaling specifically on cardiomyocyte survival, primary cardiomyocytes were cultured at normal oxygen and glucose levels and showed a dose-dependent decrease in their survival rate following Notch pathway inhibition by 2 ␥-secretase inhibitors (L-685,458 and DAPT) (Online Figure VII, A and B) at previously described noncytotoxic concentrations 22, 42 (2.5 to 10 mol/L L-685,458; 10 to 75 mol/L DAPT). Using an oxygen-glucose deprivation model (previously used in neuronal ischemia studies 43 ) to simulate cardiomyocyte ischemia in vitro, we observed statistically significant reduction in cardiomyocyte survival even when 2.5 mol/L L-685,458 or 10 mol/L DAPT were used under oxygen-glucose deprivation conditions (Online Figure VII, C) , suggesting a prosurvival role for Notch signaling in isolated cardiomyocytes.
Intramyocardial Delivery of a Notch1 Pseudoligand Favors Cardioprotection and Enhances Neovascularization
To confirm the beneficial effects of Notch activation on cardiac recovery in a clinically relevant protocol, a Notch-1activating antibody (Notch-1 Ab) 20 was injected at 2 sites (left and right) of the BZ 5 minutes after MI on wild-type mice, which were followed up by echocardiography and euthanized 4 weeks later ( Figure 7A ). Upregulation of Hes-1 and Hey-1 mRNA levels 6 hours after Notch1 antibody injection confirmed Notch signaling activation in the heart of these mice ( Figure 7B ) but not in the control group (injected with an isotype-matched hamster IgG1 antibody). One week after injury, Notch-1 Ab hearts (compared to IgG1 Ab hearts) showed minimized scar tissue deposition and did not progress to dilation and failure ( Figure 7C ). Indeed, trichrome staining proved reduction in LV scar volume and increase in LV muscle sustenance in Notch-1 Ab hearts 4 weeks after MI ( Figure 7D ). Survival rate (Online Figure VIII, A) and cardiac functional performance ( Figure 7E ) were also significantly ameliorated in Notch-1 Ab mice 2 and 4 weeks after MI, whereas expression of heart failure markers such Myh6, Myh7, and Glut-1 was decreased in the Notch-1 Ab hearts ( Figure 8A) . A concomitant reduction in transcripts encoding proapoptotic protease caspase 9 (Casp9) and upregulation of the antiapoptotic gene Bcl-2 was observed in Notch-1 Ab hearts compared to IgG1 Ab controls 4 days after MI, whereas the expression of other apoptosis-related genes (Casp3, Casp6 and Bcl-XL) remained unaltered ( Figure 8B) .
Given the requirement of Notch signaling for angiogenesis 44 and the observed NICD1 activity in endothelial and smooth muscle cells of the cardiac vessels (Online Figure I) , we assessed whether neovascularization is promoted in the Notch1 Ab hearts. Staining for the angiogenesis marker 41, 45 smooth muscle ␣-actin (␣-SMA) revealed increased number of small-diameter vessels at the BZ myocardium of Notch1 Ab hearts when compared to IgG1 Ab controls 4 weeks after infarction ( Figure 8C, top) , indicating enhanced neovascularization. Consistently, staining for the endothelial markers PECAM-1 and isolectin B4 ( Figure 8C , middle and bottom) demonstrated increased numbers of endothelial cells in the Notch1 Ab hearts. Moreover, we evaluated the levels of 5-bromodeoxyuridine incorporation at the coronary vessels of IgG1 Ab and Notch-1 Ab injected hearts 1 month after MI. The number of 5-bromodeoxyuridine-positive cells associated with coronary vessels (Border Zone) of Notch-1 Ab treated animals was increased compared to those treated with IgG1 Ab (Online Figure VIII, B ), suggesting that in contrast to the mER-Cre-mER;NICD1 model, endothelial and smooth muscle cell proliferation was also triggered by Notch-1 Ab administration leading to increased neovascularization.
Selective Silencing of Notch Signaling in Adult Cardiomyocytes Results in Impaired Cardiac Function After MI
To unravel the physiological significance of Notch activation in adult cardiomyocytes after MI, control and ␣MyHC-CRE/ϩ; Maml1 DN/DN animals were subjected to MI and followed-up by echocardiography for 4 weeks. Importantly, the ␣MyHC-CRE/ϩ;Maml1 DN/DN animals exhibited reduced survival rate (Online Figure IX, A) and severely impaired cardiac function at 1, 2, and 4 weeks after infarction, as assessed by measurements for fractional shortening, LV transverse area in systole and diastole (Online Figure IX, B through D) . Moreover, the heart to body weight ratio was increased in the ␣MyHC-CRE/ϩ;Maml1 DN/DN animals after infarction (Online Figure IX, E) , which is an indication for adverse myocardial remodeling. Taken together, these results illustrate the significance of Notch activation in adult cardiomyocytes after MI and complement our inducible gain-of-function approach.
Discussion
This study establishes a cell-autonomous role for Notch signaling in cardiomyocyte proliferation and differentiation during heart development, and demonstrates how early dysregulation of Notch signaling in the mouse embryonic cardiomyocyte compartment recapitulates the pathogenesis of human congenital HD linked to Notch mutations. Conversely, in a pathological context, induction of supplemental intracellular Notch signaling in the adult myocardium improves cardiac function, reduces replacement fibrosis and increases myocyte viability, affecting survival and providing a novel paradigm for improving clinical outcome in HD. Taken together, these observations pinpoint the cardiomyocyte as a key target of Notch action in both the embryonic and adult heart, and illustrate the critically different outcomes obtained by perturbing this signaling pathway at various life stages. Genetic manipulation of Notch signaling in the embryonic cardiomyocyte compartment led to severe cardiac malformation, including abnormal atrial and ventricular growth and septal defects, in both gain-of-function (NICD1-COE) and loss-of-function (Nkx2.5-Cre;MAML1 DN ) mutants. The hyperproliferative phenotype of NICD1-COE mutants specifically point to a critical role for Notch in regulating growth during normal cardiac morphogenesis, and defects caused by early disruption of the pathway in Nkx2.5-Cre;MAML1 DN mutants suggest that the initial steps of heart development depend on Notch signaling in the working myocardium. However, we cannot exclude the possibility that the activation of the Nkx2.5 promoter in areas surrounding the developing heart 37 could also contribute to the cardiac defects observed in the Nkx2.5-Cre;MAML1 DN mutants. It is also tempting to speculate that Notch signaling plays a role in concert with the transcription factor Nkx2.5, a master regulator of heart development, 46 because Nkx2.5 driven CRE expression comes to the expense of losing 1 allele of the Nkx2.5 gene in the Nkx2.5-Cre;MAML1 DN mutants.
Fate-mapping studies in chick 47, 48 and mouse 49,50 embryos highlight 2 distinct mesodermal heart fields that contribute cells to the developing heart. The first heart field contributes to the left ventricle and parts of the atria, 51 whereas the second heart field appears later and contributes to the right ventricle, two-thirds of the atria and parts of the outflow tract. 49, 50 Our results indicate that second heart field-derived structures are particularly sensitive to Notch signaling, as illustrated by the cardiac defects observed in NICD1-COE hearts including enlarged right atrium and RV, ASD, and VSD and significantly increased right-sided cardiomyocyte proliferation; the ASD, VSD, and abnormal RV of the Nkx2.5-Cre;MAML1 DN hearts; and the thin RV wall observed in the aMyHC-Cre;MAML1 DN hearts. This interpretation is consistent with the right-sided defects previously observed in Hey2 Ϫ/Ϫ and Jag1 ϩ/Ϫ ;Notch2 ϩ/Ϫ hearts 10, 52, 53 and with the previously reported role of Notch in left-right asymmetry determination. 54, 55 The range of phenotypes (abnormal RV, ASD, and VSD) presented by NICD1-COE and Nkx2.5-Cre;MAML1 DN mice in the present study are reminiscent of heart defects seen in humans with AGS. 3 Although human Jag1 and Notch2 mutations have linked Notch pathway with this syndrome, 7, 8, 56 it is unclear whether these mutations reflect a loss or gain of function. For example, frameshift 7,56 and missense 57 Jag1 mutations have been identified in AGS patients leading to a truncated or an intact protein product, respectively; raising the possibility that altered Notch signaling could be involved in the syndrome's expressivity. Mice deficient in the Notch target gene Hey2 or haploinsufficient for Jag1 and Notch2 partially phenocopy the AGS cardiac defects, 10, 52, 58 suggesting that loss-of-function mutations in the Notch pathway could be responsible for AGS. However, similar phenotypes presented here in both loss-and gainof-function approaches rather indicate that different levels of Notch signaling specifically in cardiomyocytes underlie the cardiac manifestations of AGS and related forms of congenital HD.
Our results also indicate that Notch signaling in cardiomyocytes is not essential for later stages of cardiac formation. Indeed, later ablation of Notch signaling in cardiomyocytes using the ␣MyHC promoter (␣MyHC-Cre;MAML1 DN mice) was compatible with life, accompanied by a subtle cardiac defect (thin RV wall) but normal functional performance at the adult stage. Consistently, late deletion of the Notch1 or Notch2 receptor specifically in ventricular cardiomyocytes using the MLC2v-Cre and SM22␣-Cre mouse line, respectively, did not result in cardiac pathology. 14, 28 Notch signaling is naturally downregulated in the adult mammalian myocardium, 22, 23 and the transient activation of endogenous Notch signaling we observed following MI is clearly insufficient to launch an effective response to cardiac damage. The amelioration of cardiac performance in mER-CRE-mER;NICD1 mice following MI is consistent with a prosurvival cell autonomous role for Notch signaling in cardiomyocytes, supported by the significant decrease in TUNEL positive cardiomyocytes observed in infarcted mER-CRE-mER;NICD1 hearts and by the reduction in cardiomyocyte viability following Notch inhibition in our in vitro cardiac ischemia platform. This model is consistent with the observed activation of the Akt survival kinase after adenoviral delivery of NICD1 in the adult heart 23 and the increased apoptosis (following hypertrophic stimuli) in the heart of mice lacking Notch1 specifically in cardiomyocytes. 14 Notch-1 pseudoligand delivery to the infarcted heart also activated survival mechanisms such as downregulation of Casp9 and upregulation of Bcl-2 at 4 days post MI, reminiscent of the synergy between Notch1 and Bcl-2 reported in a zebrafish model of T-cell leukemia. 59 Thus, our clinically relevant protocol also supports a proposed prosurvival role for Notch1 signaling.
Several in vitro and in vivo studies demonstrate that cell cycle-related genes, such as c-Myc, cyclin D1, and cyclindependent kinase inhibitors, are transcriptional targets of Notch signaling. 60 -62 In the present study, we demonstrate in vivo that NICD1 overexpression in the developing heart is sufficient to induce cardiomyocyte proliferation, whereas NICD1 inducible expression in the adult heart triggers incomplete cell cycle progression, which was evident by the increased numbers of Ki67 positive cardiomyocytes but negligible numbers of phospho-Hist3 positive cardiomyocytes. Consistently, 2 recent studies reported that Notch activation stimulates proliferation of immature cardiomyocytes in vitro, but it becomes ineffective once cardiomyocytes complete their differentiation process, 22, 24 suggesting that the outcome of Notch signaling activation in cardiomyocytes depends on the developmental context.
Because NICD1 activity has been observed in endothelial and smooth muscle cells of the cardiac vessels during adulthood, other cardiac cell types might respond positively to increased Notch signaling in the postinfarct setting. Indeed, intramyocardial delivery of a Notch1 pseudoligand during the acute phase of MI promoted neovascularization, as documented by increased numbers of ␣-SMA positive cardiac vessels and by increased numbers of PECAM-1 and isolectin-B4 positive cells. Notably, ␣-SMA has been recently described as a direct target of Notch signaling in endothelial and smooth muscle cells, 63 and endothelialspecific Notch1 inactivation impairs angiogenesis in a model of hind-limb ischemia. 64 In addition, the observation of NICD1 activity in epicardial cells after MI supports an alternative scenario for Notch1-mediated neovascularization through epicardial activation, reminiscent of regeneration in fish. 65 This study raises important considerations regarding possible adverse cardiac effects in clinical trials where Notch/␥secretase inhibition has been associated with improved clinical outcome for Alzheimer's disease 66 and colon cancer. 67 In contrast, we provide evidence that manipulation of Notch signaling in a temporally controlled and cell type-restricted manner could lead to new therapeutic avenues for individuals with congenital and acquired forms of HD. Moreover, augmentation of Notch signaling in the adult damaged heart, as demonstrated here with an inducible genetic strategy, clearly illustrates how redeployment of embryonic signaling could promote cardioprotection and regeneration. Finally, manipulation of Notch signaling in vivo using the Notch1 pseudoligand protocol provides a new clinically relevant avenue to exploit this signaling pathway in the therapy of post-MI patients.
